Because several peptides ornally found in the pituitary as within the central nervous system have been l i in lymphoid tissues and because somatostatin (soma inrelease-inhibiting hormone, SRIH) can act on cells ofthe immune system, we searched for this peptide in lymphoid organs. We demonstrated that SRIH mRNA exists in lymphoid tissue, albeit in smaller levels than in the perive region of the hypotaus, the brain region that contains the highest level of this mRNA. SRIH mRNA was found in the spleen and thymus ofmale rats and in the spleen, thymus, and bursa of Fabricius of the chicken. Its loc ton in the bursa indices that the peptide must be present in B lymphocytes since this is the site of origin of B lymphocytes in birds. The SRII concentration in these lymphoid organs as determined by radloimmunoassay was greater in the thymus than in the spleen of the rat. These concentrations were 50 times less than those found in the periventricular region of the hypodtalmus, the site ofthe perikarya ofSRIH-containing neurons. In the chicken, as in the rat, the concentration of SRII was greater in the thymus than in the spleen; it was present in the bursa ofFabridus, also in higher concentration than in the spleen.
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Fluorescence immucytochemir revealed the presence of SRIH-positive cells in dusters inside the white pulp and more dispersed within the red pulp ofthe spleen of both the rat and the chicken. The thymus from these species o contained SRIHpositive cells within the medulla and around the ctcomedullary junction. In the chicken, there were large'dusters of SRIHpositive cells in the medullary portion ofeach nodule of the bursa ofFabricius. Preabsorptionoftheprimayantiseru orreplacing this antiserum with normal rabbit serum verified the specificity of aning. Sequential immunostainingof the same sections from rat spleen using first SRIH antibody and subsequently a monoclonal antibody against a rat B-cell surface antigen revealed the presence of SRIH immunoreactivity in some, but not all, B cells. Other cell types in spleen not yet identified also stained positively with the SR.II antibody but were not reactive to monoclonal antibodies to rat Thy-1.1, a marker for all the thymic T lymphocytes. The possibility that SRIH is present in other populations ofcells in the spleen cannot be ruled out. Sequential immu nin of the same sections of rat thymus revealed the presence of SRIH immunoreactivity in a small population of T lymphocytes in the medulla, as revealed by the Thy-1.1 marker. The SRIH-positive cells were nonimmunoreactive when exposed tothe B-cell marker; however, the possibility that SRIH is present in other cells was not investigated. Thus, our results indicate that SRIH is synthesized and stored in cells of the immune system. SRHI may be secreted from these cells to exert paracine actions that alter the function of immune cells in spleen and thymus.
Somatostatin (somatotropin-release-inhibiting hormone, SRIH), originally described and isolated from the hypothalamus (1, 2) by its ability to inhibit growth hormone release occurs in a variety of endocrine and nonendocrine tissues, including other parts of the brain, pancreas, stomach, and duodenum (3, 4) . Such a wide distribution of SRIH implies the hormone has a larger functional significance that extends beyond the regulation of growth hormone secretion. There is increasing evidence that SRIH influences numerous bodily functions including the immune response. Specific receptors for SRIH have been found on lymphocytes and monocytes (4, 5) ; it exerts both stimulatory and inhibitory effects on lymphocyte proliferation (5) (6) (7) (8) , inhibits the release of colonystimulating factor from activated lymphocytes (9) , and suppresses immunoglobulin synthesis (5) . In contrast to these inhibitory actions, SRIH enhanced leukocyte-migrationinhibiting factor formation in activated lymphocytes (5) . This study was conducted to investigate the presence of SRIH and its mRNA in the spleen and thymus ofthe rat and chicken and in the bursa of Fabricius of the chicken, the organ that exclusively produces B lymphocytes in birds. (12) and purified with polyethylene glycol (12) . The presence ofthe SRIH cDNA probe was initially confirmed by digestion with the restriction enzymes Xba I and BamHI followed by separation on a 1% agarose gel and staining with ethidium bromide. An insert of -500 base pairs was detected, which is consistent with the size of the rat prepro-SRIH cDNA insert (13 tTo whom reprint requests should be addressed.
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Tie publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 25 ;uM [a-32P]CTP (800 Ci/mmol; 1 Ci = 37 GBq) was the substrate in the synthesis of the RNA probe that was used in quantitation of SRIH mRNA. After incubation at 370C for 1 h, the transcription mixture was digested with 1 unit of DNase I at 370C for 10 min, extracted with phenolchloroform, 1:1 (vol/vol), and purified by two precipitations with 2 vol of ethanol per precipitation in the presence of yeast tRNA (0.7 mg/ml). The RNA probe was washed in ice-cold 70%6 ethanol (pelleted by centrifugation) and dissolved in Tris/EDTA (TE = 10 mM Tris-HCl, pH 8.0/1 mM EDTA).
Transcript Speciflcity. Control experiments were performed to demonstrate the specificity of the binding of the probe for these assays. All controls performedi'(.e., S1
nuclease digestion and hybridization with tR14A and with sense RNA-for tyrosine hydroxylase, kindly provided by J. C. Porter (University of Texas Southwestern Medical Center, Dallas)] resulted in the absence of the nucleaseresistant fragment.
Quantification of SRIH mRNA. Total mRNA was extracted using the guanidinium/hot phenol method of Feramisco et al. (14) . Spleen and thymus from rat and chicken and bursa of Fabricius (<20 mg)' were homogenized in 0.35 ml of extraction buffer (4.5 M guanidinium thiocyanate/25 mM sodium citrate, pH 7.0/10 mM EDTA/1% Sarkosyl/1% 2-mercaptoethanol) and extracted with 0.85 ml of a mixture of phenol, 0.1 M sodium acetate (pH 5.2), and chloroform, 35:15:35 (vol/ vol). Total RNA (10 jig) was hybridized with 50,000 cpm of 32P-labeled SRIH RNA probe per tube and subjected to an S1 nuclease protection assay (15) as adapted by Kedzierski and Porter (16) . RNA probe protected by duplex formation with SRIH mRNA was analyzed by polyacrylamide gel (8% gel/8 M urea) electrophoresis, followed by autoradiography and densitometry.
RIA of SRIH. The quantity of SRIH present in the tissues was determined by RIA as-described (17) with minor modifications. The highly specific antiserum (R-11C) was generously provided by Louis-De Palatis (Dow Chemical). The characterization of this antiserum has been described (18) . In brief, the antiserum did not crossreact at a 100-fold molar excess with luteinizing-hormone-releasing factor, vasoactive intestinal peptide, thyrotropin-releasing hormone, a-melanocyte-stimulating hormone, cholecystokinin (1) (2) (3) (4) (5) (6) (7) (8) Morphdolgical Analyses. The immunofluorescence protocol used is identical to that described (20, 21) . The following antisera were used: R-11C, as described above, or JH202 (kindly supplied by S. Kentroti, University of Colorado, Denver, CO). Both antisera yielded similar results and staining was evident at dilutions from 1:100 to 1:1600. The addition of500,ug of SRIH-14 and 500 ug of SRIH-28 to 1 mlofa 1:100 dilution of antiserum resulted in a 85-90%o reduction of immunostaining. Preabsorption of a 1:1000 dilution of antiserum eliminated all immunostaining whien compared with nonpreabsorbed antisera at this same dilution. Additionally, specificity of immunostaining was further verified by using normal rabbit serum in place of the primary antisera.
To determine whether SRIH is present in B or T lympho- Fig. 2 , it is apparent that the PVN and the spleen hybridize to a species of mRNA that is w600 bases and was similar to that previously reported (22, 23) .
Having identified the SRIH mRNA in the spleen, we examined also the thymus of the rat and the spleen, thymus, and bursa of Fabricius of the chicken. The latter organ was selected since it is the exclusive site for formation of B lymphocytes in birds. The SRIH mRNA levels from rat and chicken thymus were detectable (Fig. 2) and were higher than those found in the spleen of either species. In the chicken, the bursa of Fabricius had even greater levels of SRIH mRNA than those found in spleen or thymus. The levels of SRIH mRNA in all of these organs were significantly less than those found in the PVN of the hypothalamus, which contains the highest level of mRNA for SRIH observed in any organ.
SRi Co in Organs of the Iune System. Since SRIH mRNA was present in these organs, it was anticipated that SRIH could also be detected by RIA. Indeed, low and approximately equivalent concentrations of SRIH were found in both rat and chicken, spleen (Table 1) ; there were greater levels in the thymus of both species. The bursa of Fabricius from the chicken had much higher concentrations than those present in the spleen of the chicken and levels somewhat less than those found in chicken thymus. The concentrations of SRIH in all these organs were significantly less than those found in PVN (1362 + 18 pg of SRIH per mg of protein). Loclization of SRIH in Lymphoid Organs by Imnunocytochemistry. Immunocytochemical staining of 10-jum frozen sections mounted on coverslips revealed that SRIH-positive cells were present in large clumps within both rat (Fig. 3A) and chicken (data not shown) spleen. Some sections were counterstained with hematoxylin/eosin and examination of these sections verified that some of these clumps of SRIH cells were clearly within the splenic white pulp. Other positive cells, which were outside these clumps and were more dispersed (Fig. 3C) , were localized to the red pulp.
In some experiments, after immunofluorescence and photography of the SRIH-positive cells in the rat, tissues were washed in phosphate buffer then subjected to a counterstain using specific monoclonal antibodies to either B or T lymphocytes. This reaction employed the Vectastain ABC procedure utilizing diaminobenzadine as the chromogen. Fig. 3 B and D shows the same fields as shown in Fig. 3 A and C, respectively. As can be seen with this low magnification, the large clump of SRIH-positive cells (Fig. 3A ) in spleen were found to be predominantly B lymphocytes as revealed by using the antiserum (MARK-I) to the B-cell surface antigen (Fig. 3B) . Importantly, all B lymphocytes were not positive for SRIH and, conversely, some SRIH-positive cells may be yet another cell type. This becomes more apparent by examining the more dispersed cells depicted in Fig. 3 C and D. Additionally, counterstaining SRIH-positive cells in spleen using antiserum to the surface antigen Thy-1.1 revealed no positive immunostaining in rat T cells (data not shown). These results do not rule out the possibility that other cells may contain SRIH within the spleen.
Similarly, the thymus from both species exhibited intense SRIH-positive cells in small clusters within the medulla, with less intensely stained cells around the corticomedullaryjunction. Fig. 4 depicts a representative section ofthe rat thymus. Some sections of the rat thymus were then counterstained with the MARK-I, B-cell surface marker as described above, and results indicate that the SRIH-positive cells were not B lymphocytes. Other sections were counterstained with antiThy-1.1, the T-cell marker, and those results demonstrate the presence of SRIH immunoreactivity in a small population of T lymphocytes at the corticomedullary junction (Fig. 5) . The chicken bursa of Fabricius also contained SRIHpositive cells. In this organ, the immunoreactive cells were largely confined to the medullary portion of each nodule (Fig.  6 ).
DISCUSSION
In the present study we have characterized the presence of SRIH-specific mRNA in spleen, thymus, and bursa of Fabricius by an S1 nuclease protection assay using a SRIH complementary RNA probe. These tissues contained only one species of SRIH mRNA. The length of the message in these tissues is of a similar size to that seen in the hypothalamus (22) peptide. It could be that the SRIH is only present in some specific subpopulations of B and T lymphocytes and/or that the quantity is below the sensitivity of the immunocytochemical method employed.
The fact that SRIH is contained in B lymphocytes was confirmed by its localization by immunocytochemistry to cells of the bursa of Fabricius, which is the exclusive organ forming B lymphocytes in the bird. Here it was detected in the medulla of the nodules of the bursa, which is the site of localization of the immature B cells. This suggests that SRIH is present in greater abundance in immature rather than adult B cells.
Our results provide strong evidence that SRIH is synthesized in and is present in lymphocytes in the organs of the immune system. These observations strongly suggest that SRIH may play a role in regulating the activity of these cells. It is probably released from these cells to exert paracrine actions on adjacent immune cells in lymphoid organs. Indeed, a number of such actions have been characterized. SRIH can either inhibit or stimulate lymphocyte proliferation (5) (6) (7) (8) , inhibit the release of colony-stimulating factor from activated lymphocytes (9) , and suppress immunoglobulin synthesis (5), whereas it enhances leukocyte migration-inhibiting factor formation in activated lymphocytes (7) . These actions are probably mediated by combination of SRIH with its specific receptors, which have been localized on the surface of lymphocytes and monocytes (4, 5) .
The evidence is mounting that many peptides produced in the brain and gastrointestinal tract are contained within immune cells. Examples include adrenocorticotropin hormone (24), f3-endorphin (25) , vasoactive intestinal polypeptide (26, 27) , thyrotropin (28) , chorionic gonadotropin (29), follicle-stimulating hormone (30) , luteinizing hormone (30), growth hormone (31), and finally growth-hormone-releasing hormone (32) . In this latter connection, it is tempting to speculate that growth-hormone-releasing hormone and SRIH might have antagonistic paracrine actions on immune cells just as they affect the release of growth hormone from the pituitary gland in an opposing manner. Thus, the immune system and the neuroendocrine system can produce neuropeptides, as well as interleukins and other cytokines, and also shares receptors for these neuroendocrine and immune mediators.
